Cargando…

455. Targeting of a Non-Human Coronavirus to Human Tumor Cells by Using a Bispecific Single-Chain Antibody

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Gene Therapy. Published by Elsevier Inc. 2003
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129599/ http://dx.doi.org/10.1016/S1525-0016(16)40897-X

Ejemplares similares

Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody
por: Würdinger, T, et al.
Publicado: (2005)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy
por: Zhou, Shu-juan, et al.
Publicado: (2017)

Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
por: Ahamadi-Fesharaki, Raoufeh, et al.
Publicado: (2019)

Construction and expression of D-dimer and GPIIb/IIIa single-chain bispecific antibody
por: DAN, ZHAOKUI, et al.
Publicado: (2013)

Nanocell targeting using engineered bispecific antibodies
por: Taylor, Karin, et al.
Publicado: (2014)

Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
por: Schmidt, M., et al.
Publicado: (1996)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
por: Kerns, S Jordan, et al.
Publicado: (2021)

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
por: Stadler, Christiane R., et al.
Publicado: (2015)

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody
por: Okamoto, Kayoko, et al.
Publicado: (1992)

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
por: Cheng, Ming, et al.
Publicado: (2016)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications
por: Compte, Marta, et al.
Publicado: (2014)

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
por: Huang, Shuyu, et al.
Publicado: (2020)

Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
por: Michalk, Irene, et al.
Publicado: (2014)

Common light chain chickens produce human antibodies of high affinity and broad epitope coverage for the engineering of bispecifics
por: Ching, Kathryn H., et al.
Publicado: (2021)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

A human bispecific antibody neutralizes botulinum neurotoxin serotype A
por: Lu, Jiansheng, et al.
Publicado: (2023)

Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody
por: Hao, Chao-hui, et al.
Publicado: (2015)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A
por: Zheng, Songmao, et al.
Publicado: (2020)

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
por: Ahmed, Mahiuddin, et al.
Publicado: (2015)

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
por: Gammelgaard, Odd L, et al.
Publicado: (2022)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies
por: Cooke, Heather A., et al.
Publicado: (2018)

The development of bispecific antibodies and their applications in tumor immune escape
por: Zhang, Xiaolong, et al.
Publicado: (2017)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
por: Zhang, Tiancheng, et al.
Publicado: (2023)

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
por: Malm, Magdalena, et al.
Publicado: (2016)

Insights into the molecular basis of a bispecific antibody's target selectivity
por: Mazor, Yariv, et al.
Publicado: (2015)

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
por: Mazor, Yariv, et al.
Publicado: (2017)

Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
por: Dougall, William C., et al.
Publicado: (2019)

Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
por: Pan, Zhidi, et al.
Publicado: (2022)

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_0mv3vabiosl967ai69gn55u6o7